Authors: Saiama N. Waqar
Published: 2025-05-30
Source: Full article
For more than 40 years, platinum and etoposide induction has been used as first-line treatment for both limited-stage and extensive-stage small cell lung cancer (SCLC), with initially slow progress in the development of novel systemic therapies. However, during the past few years, newer agents have emerged to alter the therapeutic scene in SCLC. These agents include several immunotherapies, selective inhibitors of oncogenic transcription, DLL3-targeting T-cell engagers such as FDA-approved tarlatamab, and antibody–drug conjugates. Results of ongoing studies of these agents may further refine the future treatment of SCLC.